Market Research Industry Reports

Graves Ophthalmopathy - Pipeline Review, H2 2016

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Graves Ophthalmopathy - Pipeline Review, H2 2016

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Graves Ophthalmopathy Pipeline Review, H2 2016, provides an overview of the Graves Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Gravesophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Graves Ophthalmopathy Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Graves Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 2 and 1 respectively.Graves Ophthalmopathy.

Graves Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves Ophthalmopathy (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves Ophthalmopathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.




Introduction 5
Global Markets Direct Report Coverage 5
Graves Ophthalmopathy Overview 6
Therapeutics Development 7
Pipeline Products for Graves Ophthalmopathy - Overview 7
Graves Ophthalmopathy - Therapeutics under Development by Companies 8
Graves Ophthalmopathy - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Graves Ophthalmopathy - Products under Development by Companies 11
Graves Ophthalmopathy - Companies Involved in Therapeutics Development 12
Genmab A/S 12
Neothetics Inc 13
Novartis AG 14
Yuhan Corp 15
Graves Ophthalmopathy - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
(fluticasone propionate + salmeterol xinafoate) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
pasireotide ER - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Synthetic Peptides for Graves Orbitopathy - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
teprotumumab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
YH-BIO - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
YH-NCE3 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Graves Ophthalmopathy - Dormant Projects 36
Graves Ophthalmopathy - Product Development Milestones 37
Featured News & Press Releases 37
Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 37
Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List Of Tables


Number of Products under Development for Graves Ophthalmopathy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Graves Ophthalmopathy - Pipeline by Genmab A/S, H2 2016 12
Graves Ophthalmopathy - Pipeline by Neothetics Inc, H2 2016 13
Graves Ophthalmopathy - Pipeline by Novartis AG, H2 2016 14
Graves Ophthalmopathy - Pipeline by Yuhan Corp, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Assessment by Combination Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Graves Ophthalmopathy - Dormant Projects, H2 2016 36

List Of Figures


Number of Products under Development for Graves Ophthalmopathy, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Graves Disease  - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Graves Disease - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Graves Disease epidemiology and market outlook for the 7MM.Markets

USD 6250View Report

Graves Disease -Epidemiology Forecast to 2027

DelveInsights Graves Disease - Epidemiology Forecast, 2027 report provides a comprehensive analysis of the Graves Disease epidemiology, providing the historical and forecasted data for the 7MM during the forecast period

USD 3250View Report

Graves Ophthalmopathy - Pipeline Review, H2 2017

Graves Ophthalmopathy - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Graves Ophthalmopathy - Pipeline Review, H2 2017, provides an overview of the Graves Ophthalmopathy

USD 2000View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2016
No. of Pages :39
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube